- Home
- FANG vs TAK Comparison
FANG vs TAK Comparison
Compare FANG & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FANG | TAK |
|---|---|---|
| Founded | 2007 | 1781 |
| Country | United States | Japan |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.3B | 43.3B |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | FANG | TAK |
|---|---|---|
| Price | $158.60 | $14.17 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 19 | 0 |
| Target Price | ★ $186.61 | N/A |
| AVG Volume (30 Days) | 1.6M | ★ 2.9M |
| Earning Date | 11-03-2025 | 10-30-2025 |
| Dividend Yield | ★ 2.52% | 1.95% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 14.37 | 0.14 |
| Revenue | $14,626,000,000.00 | ★ $29,846,840,032.00 |
| Revenue This Year | $43.41 | N/A |
| Revenue Next Year | N/A | $0.59 |
| P/E Ratio | ★ $11.04 | $101.77 |
| Revenue Growth | ★ 59.73 | N/A |
| 52 Week Low | $114.00 | $12.80 |
| 52 Week High | $180.91 | $15.69 |
Technical Indicators
Market Signals| Indicator | FANG | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 67.71 | 49.19 |
| Support Level | $143.57 | $14.38 |
| Resistance Level | $158.73 | $14.42 |
| Average True Range (ATR) | 4.62 | 0.15 |
| MACD | 1.16 | 0.01 |
| Stochastic Oscillator | 72.03 | 38.99 |
Price Performance
Historical ComparisonAbout FANG Diamondback Energy Inc.
Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2024, the company reported net proven reserves of 3.6 billion barrels of oil equivalent. Net production averaged about 598,000 barrels per day in 2024, at a ratio of 56% oil, 23% natural gas liquids, and 21% natural gas.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.